Medical Specialty Hub
Breast Cancer: Subtypes, Biomarkers & Treatment Protocols
A comprehensive clinical overview covering molecular taxonomy (HR+/HER2-, HER2+, TNBC), genomic recurrence assays, targeted antibody-drug conjugates, and clinical trials.
91%
5-Yr Relative Survival
100+
Active Clinical Trials
Clinical Overview & Pathology
Breast cancer represents a biologically diverse collection of malignancies originating primarily within the epithelial cells of the terminal ductal-lobular unit. Rather than a single disease entity, contemporary breast oncology classifies tumors based on histological grade, anatomical TNM staging, and critical hormone and growth factor receptor expressions (Estrogen Receptor [ER], Progesterone Receptor [PR], and Human Epidermal Growth Factor Receptor 2 [HER2]).
Accurate molecular profiling at diagnosis is crucial. It directly informs surgical planning, selection of neoadjuvant versus adjuvant systemic therapy, and eligibility for biomarker-matched targeted compounds.
Molecular Subtypes & Clinical Characteristics
The St. Gallen Consensus and NCCN guidelines categorize breast carcinomas into distinct subtypes:
Luminal A (HR+/HER2-)
Most prevalent subtype (~60-70%). Characterized by high ER/PR expression, negative HER2, and low Ki-67 proliferation index. Highly responsive to endocrine therapies (Aromatase Inhibitors, Tamoxifen) with favorable long-term prognosis.
Luminal B (HR+/HER2±)
Expresses ER with either HER2 positivity or high proliferation (Ki-67 > 20%). Tends to be higher grade than Luminal A and often warrants combination systemic regimens including CDK4/6 inhibitors or targeted HER2 blockade.
HER2-Enriched
Displays amplification of the ERBB2 oncogene and lack of ER/PR expression. Highly responsive to targeted dual-HER2 monoclonal antibodies (Trastuzumab + Pertuzumab) and modern antibody-drug conjugates (T-DXd).
Triple-Negative (TNBC)
Devoid of ER, PR, and HER2 overexpression (~10-15% of cases). Higher frequency in patients with germline BRCA1 mutations. Standard of care includes neoadjuvant chemo-immunotherapy (Pembrolizumab) and PARP inhibition.
Essential Biomarkers & Genomic Profiling
Routine immunohistochemistry (IHC) and multi-gene expression profiling guide precision therapy decisions:
| Biomarker / Assay |
Clinical Testing Method |
Therapeutic Implication |
| ER / PR (Hormone Receptors) |
Immunohistochemistry (IHC ≥ 1%) |
Dictates eligibility for endocrine therapies (Letrozole, Anastrozole, Fulvestrant) + CDK4/6 inhibitors. |
| HER2 / ERBB2 |
IHC (0, 1+, 2+, 3+) & Dual-Probe FISH |
Qualifies for anti-HER2 targeted agents (Trastuzumab, Pertuzumab, Enhertu [HER2-low indication]). |
| Oncotype DX / MammaPrint |
21-Gene / 70-Gene RNA RT-PCR |
Determines absolute recurrence risk and chemotherapy benefit in node-negative/early node-positive HR+ disease. |
| BRCA1 / BRCA2 Mutations |
Germline & Somatic NGS Sequencing |
Informs bilateral risk-reducing surgery and eligibility for PARP inhibitors (Olaparib, Talazoparib). |
| PIK3CA / AKT1 / PTEN |
Next-Generation Sequencing (NGS) |
Predicts endocrine resistance and qualifies metastatic patients for Alpelisib or Capivasertib. |
| PD-L1 (CPS ≥ 10) |
IHC 22C3 pharmDx Assay |
Selects locally advanced or metastatic TNBC patients for immune checkpoint inhibition with Pembrolizumab. |
Frequently Asked Questions (Clinical FAQ)
Reviewed by board-certified oncologists to provide verified answers to high-frequency patient queries.
The four main molecular subtypes are Luminal A (HR+/HER2-, low proliferation), Luminal B (HR+/HER2+ or HR+/HER2- with high Ki-67), HER2-Enriched (HR-/HER2+), and Triple-Negative Breast Cancer (TNBC: ER-, PR-, HER2-). Identifying the subtype is foundational because it dictates targeted drug eligibility and recurrence risk.
Genomic assays like Oncotype DX analyze a 21-gene expression profile in early-stage ER+/HER2- tumors to generate a Recurrence Score (0-100). This score guides oncologists on whether adjuvant systemic chemotherapy provides meaningful clinical benefit over endocrine therapy alone, sparing thousands of low-risk patients from unnecessary toxicity.
Antibody-Drug Conjugates (such as Trastuzumab deruxtecan and Sacituzumab govitecan) pair tumor-selective monoclonal antibodies with highly potent cytotoxic chemotherapeutic payloads via cleavable linkers. They deliver toxic payloads directly to tumor cells with minimal collateral systemic damage, revolutionizing care for both HER2-positive and HER2-low malignancies.
Immunotherapy using PD-1 checkpoint inhibitors (e.g., Pembrolizumab) is standard of care in high-risk early Triple-Negative Breast Cancer (TNBC) when administered with neoadjuvant chemotherapy, as well as in metastatic TNBC with tumors expressing PD-L1 (Combined Positive Score ≥ 10).
You can submit your pathology reports, diagnostic imaging, and receptor status through the ONCorg Second Opinion Assistance portal. Our clinical care coordinators connect you with certified breast medical oncologists for rapid, multidisciplinary tumor board reviews.
